Free Trial

Josh Schimmer - Cantor Fitzgerald Analyst Performance

This page shows the methodology used to calculate Josh Schimmer's recommendation performance. Listed below are links to the research notes issued, the price targets issued by the analyst, and the stock's actual price 12 months from the date the research note was issued. These rankings are based on research reports from . Rankings are updated daily.

MarketBeat Analyst Ranking:
Average 12-Month ROI of Buy and Strong Buy Recommendations: ???%

CompanyReport DateReport Date Price12-Month
Price Target
Rating12-Month
Actual Price
12-Month
ROI
Details
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/29/2025$46.59$95.00Overweight???%???%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
7/1/2025$5.47$25.00Overweight???%???%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
6/23/2025$2.46$6.00In-Line???%???%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/16/2025$6.50$30.00Overweight???%???%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
5/2/2025$177.67$280.00Outperform???%???%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4/28/2025$30.06$75.00Overweight???%???%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3/25/2025$3.92$20.00Overweight???%???%
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3/10/2025$10.13$50.00Overweight???%???%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/21/2025$37.07$95.00Overweight???%???%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2/20/2025$187.60$215.00Overweight???%???%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
9/22/2022$2.20$8.00Outperform???%???%
Icosavax, Inc. stock logo
ICVX
Icosavax
6/29/2022$7.90$18.00Outperform???%???%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
12/13/2021$8.81$20.00Outperform???%???%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11/16/2017$386.30$445.00Outperform???%???%
Insmed, Inc. stock logo
INSM
Insmed
9/5/2017$12.29$40.00Outperform???%???%


Return to Analyst Rankings